Novartis announces Xolair® approved in EU as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines
6 March 2014 | By Novartis
Novartis announced that the European Commission has approved the use of Xolair® as an add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent patients...